← All trials
NCT04786340
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2020
- Primary completion
- Apr 30, 2022
- Completion date
- May 14, 2022
- First posted
- Mar 8, 2021
- Last posted
- Aug 12, 2021
- Enrollment
- 54
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- WinSanTor, IncLead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- Eastern Virginia Medical SchoolCollaborator
- WinSanTor, IncStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.